布索珠單抗

**布索珠單抗**
單株抗體
種類	完整抗體
目標	骨硬化蛋白
臨床資料
ATC碼	未分配;
識別資訊
CAS號	1132758-87-2
ChemSpider	none;
UNII	83YOM0NEL5;
KEGG	D10094 ;
化學資訊
化學式	C6462H9852N1684O2030S46
摩爾質量	145,086.42 g·mol−1

布索珠單抗（INN：Blosozumab）是一種人源化單株抗體。它與骨硬化蛋白結合（一種成骨細胞活性的負調節因子）。阻斷硬骨素活性可以導致骨密度增加。^[1]布索珠單抗已針對男性和絕經後女性骨質疏鬆症的治療進行了研究。布索珠單抗的臨床試驗表明該抗體具有良好的耐受性並能有效產生骨合成代謝作用。^[2]

布索珠單抗由禮來公司開發。

參考資料[編輯]

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 (PDF). WHO Drug Information. 2011, 25 (2). ^{[失效連結]}
^ McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. Journal of Bone and Mineral Research. April 2014, 29 (4): 935–43. PMID 23996473. doi:10.1002/jbmr.2092 .

[1] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 (PDF). WHO Drug Information. 2011, 25 (2). ^{[失效連結]}

[2] McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. Journal of Bone and Mineral Research. April 2014, 29 (4): 935–43. PMID 23996473. doi:10.1002/jbmr.2092 .

[1]

[2]